These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1894585)

  • 1. Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia.
    Radin AI; Buckley P; Duffy TP
    Hematol Pathol; 1991; 5(2):83-8. PubMed ID: 1894585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia.
    Mohite U; Pathare A; al Kindi S; Hiwase D; Vadakkepat N; Knox-Macaulay H
    Haematologia (Budap); 2002; 32(4):495-9. PubMed ID: 12803124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.
    Lévy V; Bourgarit A; Delmer A; Legrand O; Baudard M; Rio B; Zittoun R
    Am J Hematol; 1996 Dec; 53(4):239-41. PubMed ID: 8948661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenectomy for agnogenic myeloid metaplasia.
    Coon WW; Liepman MK
    Surg Gynecol Obstet; 1982 Apr; 154(4):561-3. PubMed ID: 7064091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival.
    Varki A; Lottenberg R; Griffith R; Reinhard E
    Medicine (Baltimore); 1983 Nov; 62(6):353-71. PubMed ID: 6633248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agnogenic myeloid metaplasia; its current managment.
    Silverstein MN
    Minn Med; 1970 Mar; 53(3):257-9. PubMed ID: 5415744
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
    Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases.
    Brenner B; Nagler A; Tatarsky I; Hashmonai M
    Arch Intern Med; 1988 Nov; 148(11):2501-5. PubMed ID: 3190384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
    Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
    Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Tefferi A
    Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
    Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
    Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Case report and review of the literature.
    Knobel B; Melamud E; Virag I; Meytes D
    Acta Haematol; 1993; 89(2):104-7. PubMed ID: 8503241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of myeloid metaplasia with myelofibrosis and hairy-cell leukemia.
    Subramanian VP; Gomez GA; Han T; Kim U; Minowada J; Sandberg A
    Arch Intern Med; 1985 Jan; 145(1):164-6. PubMed ID: 3970633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coexistence of myelofibrosis and collagen diseases].
    Bistue R; Gallo de Sprazzato ME; Scognamillo CD; Porretta de Croceri L; Estevez MM; Guerra D
    Medicina (B Aires); 1990; 50(3):248-50. PubMed ID: 2130212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Agnogenic myelofibrosis].
    Avilés A; Monroy L; Ambriz R; Butrón L; Pizzuto J
    Gac Med Mex; 1981 Mar; 117(3):110-7. PubMed ID: 7327351
    [No Abstract]   [Full Text] [Related]  

  • 19. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion therapy in autoimmune hemolytic anemia.
    Jefferies LC
    Hematol Oncol Clin North Am; 1994 Dec; 8(6):1087-104. PubMed ID: 7860438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.